A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjects
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs DWP 09031 (Primary)
- Indications Delirium dementia amnestic cognitive disorders
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 15 Feb 2012 Actual initiation date (18 Jan 2012) added as reported by Korean Clinical Trials Register.
- 15 Feb 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register.
- 15 Feb 2012 Official Title amended as reported by Korean Clinical Trials Register.